NuVasive (NASDAQ: NUVA) and Integra Lifesciences (NASDAQ:IART) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation.


This table compares NuVasive and Integra Lifesciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NuVasive 6.36% 13.65% 6.17%
Integra Lifesciences 4.52% 16.35% 6.83%

Analyst Ratings

This is a breakdown of recent ratings and price targets for NuVasive and Integra Lifesciences, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NuVasive 0 3 12 0 2.80
Integra Lifesciences 0 7 3 0 2.30

NuVasive currently has a consensus target price of $71.64, indicating a potential upside of 38.33%. Integra Lifesciences has a consensus target price of $51.88, indicating a potential downside of 2.73%. Given NuVasive’s stronger consensus rating and higher possible upside, analysts clearly believe NuVasive is more favorable than Integra Lifesciences.

Earnings & Valuation

This table compares NuVasive and Integra Lifesciences’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NuVasive $962.07 million 2.74 $37.14 million $1.19 43.52
Integra Lifesciences $992.08 million 4.22 $74.56 million $0.61 87.43

Integra Lifesciences has higher revenue and earnings than NuVasive. NuVasive is trading at a lower price-to-earnings ratio than Integra Lifesciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

87.6% of Integra Lifesciences shares are owned by institutional investors. 1.2% of NuVasive shares are owned by insiders. Comparatively, 21.5% of Integra Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

NuVasive has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Integra Lifesciences has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.


Integra Lifesciences beats NuVasive on 8 of the 14 factors compared between the two stocks.

NuVasive Company Profile

Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with's FREE daily email newsletter.